T Cell Receptor Profiling in Type 1 Diabetes

Current Diabetes Reports

Volumn 17, Issue 11, 2017, Pages

  Jacobsen, Laura M ^a   Posgai, Amanda ^a   Seay, Howard R ^a   Haller, Michael J ^a   Brusko, Todd M ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Adaptive immunity; Autoimmunity; Human immune repertoire; Immunosequencing; T cell receptor; Type 1 diabetes

Indexed keywords

BIOLOGICAL MARKER; CHIMERIC ANTIGEN RECEPTOR; EPITOPE; HLA ANTIGEN; RIBOSOME PROTEIN; T LYMPHOCYTE RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

AMINO ACID SEQUENCE; BLOOD ANALYSIS; DIAGNOSTIC ACCURACY; DRUG TARGETING; HUMAN; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; MALIGNANT NEOPLASM; METHODOLOGY; NEXT GENERATION SEQUENCING; NONHUMAN; ORGAN DONOR; PANCREAS ISLET CELL; PANCREAS TRANSPLANTATION; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN ENGINEERING; REVIEW; RISK FACTOR; TARGET CELL; ANIMAL; AUTOIMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; T LYMPHOCYTE;

ANIMALS; AUTOIMMUNITY; BIOMARKERS; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNOTHERAPY; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 85031429533     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-017-0946-4     Document Type: Review

References (266)

1. Wicker LS, Clark J, Fraser HI, Garner VE, Gonzalez-Munoz A, Healy B, et al. Type 1 diabetes genes and pathways shared by humans and NOD mice. J Autoimmun. 2005;25(Suppl):29–33. https://doi.org/10.1016/j.jaut.2005.09.009.
2. Giarratana N, Penna G, Adorini L. Animal models of spontaneous autoimmune disease: type 1 diabetes in the nonobese diabetic mouse. Methods Mol Biol. 2007;380:285–311. https://doi.org/10.1007/978-1-59745-395-0_17.
3. Sosinowski T, Eisenbarth GS. Type 1 diabetes: primary antigen/peptide/register/trimolecular complex. Immunol Res. 2013;55(1–3):270–6. https://doi.org/10.1007/s12026-012-8367-6.
4. Boldison J, Wong FS. Immune and pancreatic beta cell interactions in type 1 diabetes. Trends Endocrinol Metab. 2016;27(12):856–67. https://doi.org/10.1016/j.tem.2016.08.007.
5. Christianson SW, Shultz LD, Leiter EH. Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice. Relative contributions of CD4+ and CD8+ T-cells from diabetic versus prediabetic NOD.NON-Thy-1a donors. Diabetes. 1993;42(1):44–55.
6. Ikehara S, Ohtsuki H, Good RA, Asamoto H, Nakamura T, Sekita K, et al. Prevention of type I diabetes in nonobese diabetic mice by allogenic bone marrow transplantation. Proc Natl Acad Sci U S A. 1985;82(22):7743–7.
7. Lampeter EF, Homberg M, Quabeck K, Schaefer UW, Wernet P, Bertrams J, et al. Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation. Lancet. 1993;341(8855):1243–4.
8. Lampeter EF, McCann SR, Kolb H. Transfer of diabetes type 1 by bone-marrow transplantation. Lancet. 1998;351(9102):568–9. https://doi.org/10.1016/s0140-6736(05)78555-x.
9. Van Belle TL, Taylor P, von Herrath MG. Mouse models for type 1 diabetes. Drug Discov Today Dis Models. 2009;6(2):41–5. https://doi.org/10.1016/j.ddmod.2009.03.008.
10. Campbell-Thompson M, Fu A, Kaddis JS, Wasserfall C, Schatz DA, Pugliese A, et al. Insulitis and beta-cell mass in the natural history of type 1 diabetes. Diabetes. 2016;65(3):719–31. https://doi.org/10.2337/db15-0779.
11. in't Veld P. Rodent versus human insulitis: why the huge disconnect? Curr Opin Endocrinol Diabetes Obes. 2015;22(2):86–90. https://doi.org/10.1097/med.0000000000000135.
12. In't Veld P. Insulitis in human type 1 diabetes: the quest for an elusive lesion. Islets. 2011;3(4):131–8.
13. Herold KC, Usmani-Brown S, Ghazi T, Lebastchi J, Beam CA, Bellin MD, et al. Beta cell death and dysfunction during type 1 diabetes development in at-risk individuals. J Clin Invest. 2015;125(3):1163–73. https://doi.org/10.1172/jci78142.
14. Atkinson MA, Bluestone JA, Eisenbarth GS, Hebrok M, Herold KC, Accili D, et al. How does type 1 diabetes develop?: the notion of homicide or beta-cell suicide revisited. Diabetes. 2011;60(5):1370–9. https://doi.org/10.2337/db10-1797.
15. Herold KC, Brooks-Worrell B, Palmer J, Dosch HM, Peakman M, Gottlieb P, et al. Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes. Diabetes. 2009;58(11):2588–95. https://doi.org/10.2337/db09-0249.
16. Arif S, Leete P, Nguyen V, Marks K, Nor NM, Estorninho M, et al. Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes. Diabetes. 2014;63(11):3835–45. https://doi.org/10.2337/db14-0365.
17. Roep BO, Atkinson MA, van Endert PM, Gottlieb PA, Wilson SB, Sachs JA. Autoreactive T cell responses in insulin-dependent (type 1) diabetes mellitus. Report of the first international workshop for standardization of T cell assays. J Autoimmun. 1999;13(2):267–82. https://doi.org/10.1006/jaut.1999.0312 S0896-8411(99)90312-8.
18. Mallone R, Scotto M, Janicki CN, James EA, Fitzgerald-Miller L, Wagner R, et al. Immunology of diabetes society T-cell workshop: HLA class I tetramer-directed epitope validation initiative T-cell workshop report-HLA class I tetramer validation initiative. Diabetes Metab Res Rev. 2011;27(8):720–6. https://doi.org/10.1002/dmrr.1243.
19. Mannering SI, Wong FS, Durinovic-Belló I, Brooks-Worrell B, Tree TI, Cilio CM, et al. Current approaches to measuring human islet-antigen specific T cell function in type 1 diabetes. Clin Exp Immunol. 2010;162(2):197–209. https://doi.org/10.1111/j.1365-2249.2010.04237.x.
20. Thome J, Yudanin N, Ohmura Y, Kubota M, Grinshpun B, Sathaliyawala T, et al. Spatial map of human T cell compartmentalization and maintenance over decades of life. Cell. 2014;159(4):814–28.
21. Farber D, Yudanin N, Restifo N. Human memory T cells: generation, compartmentalization and homeostasis. Nature Rev Immunol. 2014;14(1):24–35.
22. Li L, He Q, Garland A, Yi Z, Aybar LT, Kepler TB, et al. Beta cell-specific CD4+ T cell clonotypes in peripheral blood and the pancreatic islets are distinct. J Immunol (Baltimore, Md: 1950). 2009;183(11):7585–91. https://doi.org/10.4049/jimmunol.0901587.
23. • Eugster A, Lindner A, Catani M, Heninger AK, Dahl A, Klemroth S, et al. High diversity in the TCR repertoire of GAD65 autoantigen-specific human CD4+ T cells. J of Immunol (Baltimore, Md: 1950). 2015;194(6):2531–8. https://doi.org/10.4049/jimmunol.1403031. This paper represents a comprehensive list of GAD65-reactive TCRs isolated by tetramer staining and then characterized via immunosequencing.
24. Fuchs YF, Eugster A, Dietz S, Sebelefsky C, Kuhn D, Wilhelm C, et al. CD8+ T cells specific for the islet autoantigen IGRP are restricted in their T cell receptor chain usage. Sci Rep. 2017;7:44661. https://doi.org/10.1038/srep44661.
25. Skowera A, Ladell K, McLaren JE, Dolton G, Matthews KK, Gostick E, et al. Beta-cell-specific CD8 T cell phenotype in type 1 diabetes reflects chronic autoantigen exposure. Diabetes. 2015;64(3):916–25. https://doi.org/10.2337/db14-0332.
26. Erlich H, Valdes AM, Noble J, Carlson JA, Varney M, Concannon P, et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes. 2008;57(4):1084–92. https://doi.org/10.2337/db07-1331.
27. Jeker LT, Bour-Jordan H, Bluestone JA. Breakdown in peripheral tolerance in type 1 diabetes in mice and humans. Cold Spring Harb Perspect Med. 2012;2(3):a007807. https://doi.org/10.1101/cshperspect.a007807.
28. Lempainen J, Laine AP, Hammais A, Toppari J, Simell O, Veijola R, et al. Non-HLA gene effects on the disease process of type 1 diabetes: from HLA susceptibility to overt disease. J Autoimmun. 2015;61:45–53. https://doi.org/10.1016/j.jaut.2015.05.005.
29. Noble JA, Valdes AM. Genetics of the HLA region in the prediction of type 1 diabetes. Curr Diabetes Rep. 2011;11(6):533–42. https://doi.org/10.1007/s11892-011-0223-x.
30. Al-Hussein KA, Rama NR, Ahmad M, Rozemuller E, Tilanus MG. HLA-DPB1*0401 is associated with dominant protection against type 1 diabetes in the general Saudi population and in subjects with a high-risk DR/DQ haplotype. Eur J Immunogenet. 2003;30(2):115–9.
31. Kaddis JS, Pugliese A, Atkinson MA. A run on the biobank: what have we learned about type 1 diabetes from the nPOD tissue repository? Curr Opin Endocrinol Diabetes Obes. 2015;22(4):290–5. https://doi.org/10.1097/med.0000000000000171.
32. In't Veld P, Lievens D, De Grijse J, Ling Z, Van der Auwera B, Pipeleers-Marichal M, et al. Screening for insulitis in adult autoantibody-positive organ donors. Diabetes. 2007;56(9):2400–4. https://doi.org/10.2337/db07-0416.
33. Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol. 2009;155(2):173–81. https://doi.org/10.1111/j.1365-2249.2008.03860.x.
34. Coppieters KT, Dotta F, Amirian N, Campbell PD, Kay TW, Atkinson MA, et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med. 2012;209(1):51–60. https://doi.org/10.1084/jem.20111187.
35. Tian J, Zekzer D, Lu Y, Dang H, Kaufman DL. B cells are crucial for determinant spreading of T cell autoimmunity among beta cell antigens in diabetes-prone nonobese diabetic mice. J Immunol. 2006;176(4):2654–61.
36. • Burke GW 3rd, Vendrame F, Virdi SK, Ciancio G, Chen L, Ruiz P, et al. Lessons from pancreas transplantation in type 1 diabetes: recurrence of islet autoimmunity. Curr Diab Rep. 2015;15(12):121. https://doi.org/10.1007/s11892-015-0691-5. This paper provides longitudinal descriptions of autoreactive T cell clones appearing in conjunciton with autoantibodies in patients with recurring type 1 diabetes after pancreas transplant.
37. Roep BO, Peakman M. Antigen targets of type 1 diabetes autoimmunity. Cold Spring Harb Perspect Med. 2012;2(4):a007781. https://doi.org/10.1101/cshperspect.a007781.
38. • Seay HR, Yusko E, Rothweiler SJ, Zhang L, Posgai AL, Campbell-Thompson M, et al. Tissue distribution and clonal diversity of the T and B cell repertoire in type 1 diabetes. JCI Insight. 2016;1(20):e88242. https://doi.org/10.1172/jci.insight.88242. This paper represents the first report characterizing the adaptive immune repertoire in multiple organs and tissues isolated from type 1 diabetes versus control organ donors.
39. Unger WW, Velthuis J, Abreu JR, Laban S, Quinten E, Kester MG, et al. Discovery of low-affinity preproinsulin epitopes and detection of autoreactive CD8 T-cells using combinatorial MHC multimers. J Autoimmun. 2011;37(3):151–9. https://doi.org/10.1016/j.jaut.2011.05.012.
40. Danke NA, Koelle DM, Yee C, Beheray S, Kwok WW. Autoreactive T cells in healthy individuals. J Immunol (Baltimore, Md: 1950). 2004;172(10):5967–72.
41. Reijonen H, Novak EJ, Kochik S, Heninger A, Liu AW, Kwok WW, et al. Detection of GAD65-specific T-cells by major histocompatibility complex class II tetramers in type 1 diabetic patients and at-risk subjects. Diabetes. 2002;51(5):1375–82. https://doi.org/10.2337/diabetes.51.5.1375.
42. Mallone R, Martinuzzi E, Blancou P, Novelli G, Afonso G, Dolz M, et al. CD8+ T-cell responses identify beta-cell autoimmunity in human type 1 diabetes. Diabetes. 2007;56(3):613–21. https://doi.org/10.2337/db06-1419.
43. Han A, Glanville J, Hansmann L, Davis MM. Linking T-cell receptor sequence to functional phenotype at the single-cell level. Nat Biotechnol. 2014;32(7):684–92. https://doi.org/10.1038/nbt.2938.
44. Reijonen H, Mallone R, Heninger AK, Laughlin EM, Kochik SA, Falk B, et al. GAD65-specific CD4+ T-cells with high antigen avidity are prevalent in peripheral blood of patients with type 1 diabetes. Diabetes. 2004;53(8):1987–94.
45. Gebe JA, Yue BB, Unrath KA, Falk BA, Nepom GT. Restricted autoantigen recognition associated with deletional and adaptive regulatory mechanisms. J Immunol (Baltimore, Md: 1950). 2009;183(1):59–65. https://doi.org/10.4049/jimmunol.0804046.
46. Codina-Busqueta E, Scholz E, Munoz-Torres PM, Roura-Mir C, Costa M, Xufre C, et al. TCR bias of in vivo expanded T cells in pancreatic islets and spleen at the onset in human type 1 diabetes. J Immunol (Baltimore, Md: 1950). 2011;186(6):3787–97. https://doi.org/10.4049/jimmunol.1002423.
47. Marrero I, Aguilera C, Hamm DE, Quinn A, Kumar V. High-throughput sequencing reveals restricted TCR Vbeta usage and public TCRbeta clonotypes among pancreatic lymph node memory CD4(+) T cells and their involvement in autoimmune diabetes. Mol Immunol. 2016;74:82–95. https://doi.org/10.1016/j.molimm.2016.04.013.
48. Klarenbeek PL, de Hair MJ, Doorenspleet ME, van Schaik BD, Esveldt RE, van de Sande MG, et al. Inflamed target tissue provides a specific niche for highly expanded T-cell clones in early human autoimmune disease. Ann Rheum Dis. 2012;71(6):1088–93. https://doi.org/10.1136/annrheumdis-2011-200612.
49. Kloverpris HN, McGregor R, McLaren JE, Ladell K, Harndahl M, Stryhn A, et al. CD8+ TCR bias and immunodominance in HIV-1 infection. J Immunol. 2015;194(11):5329–45. https://doi.org/10.4049/jimmunol.1400854.
50. Wieckowski S, Baumgaertner P, Corthesy P, Voelter V, Romero P, Speiser DE, et al. Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients. J Immunol. 2009;183(8):5397–406. https://doi.org/10.4049/jimmunol.0901460.
51. Niu J, Jia Q, Ni Q, Yang Y, Chen G, Yang X, et al. Association of CD8(+) T lymphocyte repertoire spreading with the severity of DRESS syndrome. Sci Rep. 2015;5:9913. https://doi.org/10.1038/srep09913.
52. Cukalac T, Kan WT, Dash P, Guan J, Quinn KM, Gras S, et al. Paired TCRalphabeta analysis of virus-specific CD8(+) T cells exposes diversity in a previously defined ‘narrow’ repertoire. Immunol Cell Biol. 2015;93(9):804–14. https://doi.org/10.1038/icb.2015.44.
53. Koning D, Costa AI, Hasrat R, Grady BP, Spijkers S, Nanlohy N, et al. In vitro expansion of antigen-specific CD8(+) T cells distorts the T-cell repertoire. J Immunol Methods. 2014;405:199–203. https://doi.org/10.1016/j.jim.2014.01.013.
54. Miconnet I, Marrau A, Farina A, Taffe P, Vigano S, Harari A, et al. Large TCR diversity of virus-specific CD8 T cells provides the mechanistic basis for massive TCR renewal after antigen exposure. J Immunol. 2011;186(12):7039–49. https://doi.org/10.4049/jimmunol.1003309.
55. Remmerswaal EB, Klarenbeek PL, Alves NL, Doorenspleet ME, van Schaik BD, Esveldt RE, et al. Clonal evolution of CD8+ T cell responses against latent viruses: relationship among phenotype, localization, and function. J Virol. 2015;89(1):568–80. https://doi.org/10.1128/jvi.02003-14.
56. Nakanishi K, Kukita Y, Segawa H, Inoue N, Ohue M, Kato K. Characterization of the T-cell receptor beta chain repertoire in tumor-infiltrating lymphocytes. Cancer Med. 2016;5(9):2513–21. https://doi.org/10.1002/cam4.828.
57. Kent SC, Chen Y, Bregoli L, Clemmings SM, Kenyon NS, Ricordi C, et al. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature. 2005;435(7039):224–8. https://doi.org/10.1038/nature03625.
58. Gil A, Yassai MB, Naumov YN, Selin LK. Narrowing of human influenza A virus-specific T cell receptor alpha and beta repertoires with increasing age. J Virol. 2015;89(8):4102–16. https://doi.org/10.1128/jvi.03020-14.
59. Conrad JA, Ramalingam RK, Smith RM, Barnett L, Lorey SL, Wei J, et al. Dominant clonotypes within HIV-specific T cell responses are programmed death-1high and CD127low and display reduced variant cross-reactivity. J Immunol. 2011;186(12):6871–85. https://doi.org/10.4049/jimmunol.1004234.
60. Salou M, Garcia A, Michel L, Gainche-Salmon A, Loussouarn D, Nicol B, et al. Expanded CD8 T-cell sharing between periphery and CNS in multiple sclerosis. Ann Clin Transl Neurol. 2015;2(6):609–22. https://doi.org/10.1002/acn3.199.
61. Kitaura K, Fujii Y, Hayasaka D, Matsutani T, Shirai K, Nagata N, et al. High clonality of virus-specific T lymphocytes defined by TCR usage in the brains of mice infected with West Nile virus. J Immunol. 2011;187(8):3919–30. https://doi.org/10.4049/jimmunol.1100442.
62. Miles JJ, Thammanichanond D, Moneer S, Nivarthi UK, Kjer-Nielsen L, Tracy SL, et al. Antigen-driven patterns of TCR bias are shared across diverse outcomes of human hepatitis C virus infection. J Immunol. 2011;186(2):901–12. https://doi.org/10.4049/jimmunol.1003167.
63. Toivonen R, Arstila TP, Hanninen A. Islet-associated T-cell receptor-beta CDR sequence repertoire in prediabetic NOD mice reveals antigen-driven T-cell expansion and shared usage of VbetaJbeta TCR chains. Mol Immunol. 2015;64(1):127–35. https://doi.org/10.1016/j.molimm.2014.11.009.
64. Raffegerst SH, Hoelzlwimmer G, Kunder S, Mysliwietz J, Quintanilla-Martinez L, Schendel DJ. Diverse hematological malignancies including Hodgkin-like lymphomas develop in chimeric MHC class II transgenic mice. PLoS One. 2009;4(12):e8539. https://doi.org/10.1371/journal.pone.0008539.
65. Yu XG, Lichterfeld M, Chetty S, Williams KL, Mui SK, Miura T, et al. Mutually exclusive T-cell receptor induction and differential susceptibility to human immunodeficiency virus type 1 mutational escape associated with a two-amino-acid difference between HLA class I subtypes. J Virol. 2007;81(4):1619–31. https://doi.org/10.1128/jvi.01580-06.
66. Zang Y, Martinez L, Fernandez I, Pignac-Kobinger J, Greidinger EL. Conservation of pathogenic TCR homology across class II restrictions in anti-ribonucleoprotein autoimmunity: extended efficacy of T cell vaccine therapy. J Immunol. 2014;192(9):4093–102. https://doi.org/10.4049/jimmunol.1203197.
67. Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, et al. PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014;124(5):2246–59. https://doi.org/10.1172/jci73639.
68. Zhang Q, Jia Q, Deng T, Song B, Li L. Heterogeneous expansion of CD4+ tumor-infiltrating T-lymphocytes in clear cell renal cell carcinomas. Biochem Biophys Res Commun. 2015;458(1):70–6. https://doi.org/10.1016/j.bbrc.2015.01.069.
69. Mamedov IZ, Britanova OV, Bolotin DA, Chkalina AV, Staroverov DB, Zvyagin IV, et al. Quantitative tracking of T cell clones after haematopoietic stem cell transplantation. EMBO Mol Med. 2011;3(4):201–7. https://doi.org/10.1002/emmm.201100129.
70. Dong L, Li P, Oenema T, McClurkan CL, Koelle DM. Public TCR use by herpes simplex virus-2-specific human CD8 CTLs. J Immunol. 2010;184(6):3063–71. https://doi.org/10.4049/jimmunol.0903622.
71. Jensen T, Hansen P, Faurskov Nielsen A, Meldal M, Komba S, Werdelin O. Shared structural motifs in TCR of glycopeptide-recognizing T cell hybridomas. Eur J Immunol. 1999;29(9):2759–68. https://doi.org/10.1002/(sici)1521-4141(199909)29:09<2759::aid-immu2759>3.0.co;2-4.
72. Price DA, Brenchley JM, Ruff LE, Betts MR, Hill BJ, Roederer M, et al. Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses. J Exp Med. 2005;202(10):1349–61. https://doi.org/10.1084/jem.20051357.
73. La Gruta NL, Thomas PG, Webb AI, Dunstone MA, Cukalac T, Doherty PC, et al. Epitope-specific TCRbeta repertoire diversity imparts no functional advantage on the CD8+ T cell response to cognate viral peptides. Proc Natl Acad Sci U S A. 2008;105(6):2034–9. https://doi.org/10.1073/pnas.0711682102.
74. Klarenbeek PL, Remmerswaal EB, ten Berge IJ, Doorenspleet ME, van Schaik BD, Esveldt RE, et al. Deep sequencing of antiviral T-cell responses to HCMV and EBV in humans reveals a stable repertoire that is maintained for many years. PLoS Pathog. 2012;8(9):e1002889. https://doi.org/10.1371/journal.ppat.1002889.
75. Rangarajan H, Yassai M, Subramanian H, Komorowski R, Whitaker M, Gorski J, et al. Emergence of T cells that recognize nonpolymorphic antigens during graft-versus-host disease. Blood. 2012;119(26):6354–64. https://doi.org/10.1182/blood-2012-01-401596.
76. Cohen GB, Islam SA, Noble MS, Lau C, Brander C, Altfeld MA, et al. Clonotype tracking of TCR repertoires during chronic virus infections. Virology. 2002;304(2):474–84.
77. Simons BC, Vancompernolle SE, Smith RM, Wei J, Barnett L, Lorey SL, et al. Despite biased TRBV gene usage against a dominant HLA B57-restricted epitope, TCR diversity can provide recognition of circulating epitope variants. J Immunol. 2008;181(7):5137–46.
78. Serana F, Sottini A, Caimi L, Palermo B, Natali PG, Nistico P, et al. Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients. J Transl Med. 2009;7:21. https://doi.org/10.1186/1479-5876-7-21.
79. Iglesias MC, Almeida JR, Fastenackels S, van Bockel DJ, Hashimoto M, Venturi V, et al. Escape from highly effective public CD8+ T-cell clonotypes by HIV. Blood. 2011;118(8):2138–49. https://doi.org/10.1182/blood-2011-01-328781.
80. Sonntag K, Eckert F, Welker C, Muller H, Muller F, Zips D, et al. Chronic graft-versus-host-disease in CD34(+)-humanized NSG mice is associated with human susceptibility HLA haplotypes for autoimmune disease. J Autoimmun. 2015;62:55–66. https://doi.org/10.1016/j.jaut.2015.06.006.
81. Palermo B, Del Bello D, Sottini A, Serana F, Ghidini C, Gualtieri N, et al. Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of melan-a-specific, tumor-reactive CTL in melanoma patients. Cancer Rses. 2010;70(18):7084–92. https://doi.org/10.1158/0008-5472.can-10-1326.
82. Kedzierska K, Venturi V, Field K, Davenport MP, Turner SJ, Doherty PC. Early establishment of diverse T cell receptor profiles for influenza-specific CD8(+)CD62L(hi) memory T cells. Proc Natl Acad Sci U S A. 2006;103(24):9184–9. https://doi.org/10.1073/pnas.0603289103.
83. Sun X, Fujiwara M, Shi Y, Kuse N, Gatanaga H, Appay V, et al. Superimposed epitopes restricted by the same HLA molecule drive distinct HIV-specific CD8+ T cell repertoires. J Immunol. 2014;193(1):77–84. https://doi.org/10.4049/jimmunol.1400375.
84. Chung WH, Pan RY, Chu MT, Chin SW, Huang YL, Wang WC, et al. Oxypurinol-specific T cells possess preferential TCR clonotypes and express granulysin in allopurinol-induced severe cutaneous adverse reactions. J Invest Dermatol. 2015;135(9):2237–48. https://doi.org/10.1038/jid.2015.165.
85. Casanova JL, Romero P, Widmann C, Kourilsky P, Maryanski JL. T cell receptor genes in a series of class I major histocompatibility complex-restricted cytotoxic T lymphocyte clones specific for a plasmodium berghei nonapeptide: implications for T cell allelic exclusion and antigen-specific repertoire. J Exp Med. 1991;174(6):1371–83.
86. Trautmann L, Rimbert M, Echasserieau K, Saulquin X, Neveu B, Dechanet J, et al. Selection of T cell clones expressing high-affinity public TCRs within human cytomegalovirus-specific CD8 T cell responses. J Immunol. 2005;175(9):6123–32.
87. Sainz-Perez A, Lim A, Lemercier B, Leclerc C. The T-cell receptor repertoire of tumor-infiltrating regulatory T lymphocytes is skewed toward public sequences. Cancer Res. 2012;72(14):3557–69. https://doi.org/10.1158/0008-5472.can-12-0277.
88. Iancu EM, Corthesy P, Baumgaertner P, Devevre E, Voelter V, Romero P, et al. Clonotype selection and composition of human CD8 T cells specific for persistent herpes viruses varies with differentiation but is stable over time. J Immunol. 2009;183(1):319–31. https://doi.org/10.4049/jimmunol.0803647.
89. Sherwood AM, Emerson RO, Scherer D, Habermann N, Buck K, Staffa J, et al. Tumor-infiltrating lymphocytes in colorectal tumors display a diversity of T cell receptor sequences that differ from the T cells in adjacent mucosal tissue. Cancer Immunol Immunother. 2013;62(9):1453–61. https://doi.org/10.1007/s00262-013-1446-2.
90. Motz GT, Eppert BL, Sun G, Wesselkamper SC, Linke MJ, Deka R, et al. Persistence of lung CD8 T cell oligoclonal expansions upon smoking cessation in a mouse model of cigarette smoke-induced emphysema. J Immunol. 2008;181(11):8036–43.
91. Costello PJ, Winchester RJ, Curran SA, Peterson KS, Kane DJ, Bresnihan B, et al. Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen driven. J Immunol. 2001;166(4):2878–86.
92. Wu HD, Maurer MS, Friedman RA, Marboe CC, Ruiz-Vazquez EM, Ramakrishnan R, et al. The lymphocytic infiltration in calcific aortic stenosis predominantly consists of clonally expanded T cells. J Immunol. 2007;178(8):5329–39.
93. Miles JJ, Bulek AM, Cole DK, Gostick E, Schauenburg AJ, Dolton G, et al. Genetic and structural basis for selection of a ubiquitous T cell receptor deployed in Epstein-Barr virus infection. PLoS Pathog. 2010;6(11):e1001198. https://doi.org/10.1371/journal.ppat.1001198.
94. Chen G, Yang X, Ko A, Sun X, Gao M, Zhang Y, et al. Sequence and structural analyses reveal distinct and highly diverse human CD8+ TCR repertoires to immunodominant viral antigens. Cell Rep. 2017;19(3):569–83. https://doi.org/10.1016/j.celrep.2017.03.072.
95. Wallace ME, Bryden M, Cose SC, Coles RM, Schumacher TN, Brooks A, et al. Junctional biases in the naive TCR repertoire control the CTL response to an immunodominant determinant of HSV-1. Immunity. 2000;12(5):547–56.
96. Protheroe AS, Pickard C, Johnson PW, Craddock T, Shefta J, Short K, et al. Persistence of clonal T-cell expansions following high-dose chemotherapy and autologous peripheral blood progenitor cell rescue. Br J Haematol. 2000;111(3):766–73.
97. Manne J, Mastrangelo MJ, Sato T, Berd D. TCR rearrangement in lymphocytes infiltrating melanoma metastases after administration of autologous dinitrophenyl-modified vaccine. J Immunol. 2002;169(6):3407–12.
98. Nakasone H, Tanaka Y, Yamazaki R, Terasako K, Sato M, Sakamoto K, et al. Single-cell T-cell receptor-beta analysis of HLA-A*2402-restricted CMV- pp65-specific cytotoxic T-cells in allogeneic hematopoietic SCT. Bone Marrow Transplant. 2014;49(1):87–94. https://doi.org/10.1038/bmt.2013.122.
99. Kedzierska K, Turner SJ, Doherty PC. Conserved T cell receptor usage in primary and recall responses to an immunodominant influenza virus nucleoprotein epitope. Proc Natl Acad Sci U S A. 2004;101(14):4942–7. https://doi.org/10.1073/pnas.0401279101.
100. Li LP, Lampert JC, Chen X, Leitao C, Popovic J, Muller W, et al. Transgenic mice with a diverse human T cell antigen receptor repertoire. Nat Med. 2010;16(9):1029–34. https://doi.org/10.1038/nm.2197.
101. Klinger M, Pepin F, Wilkins J, Asbury T, Wittkop T, Zheng J, et al. Multiplex identification of antigen-specific T cell receptors using a combination of immune assays and immune receptor sequencing. PLoS One. 2015;10(10):e0141561. https://doi.org/10.1371/journal.pone.0141561.
102. Munson DJ, Egelston CA, Chiotti KE, Parra ZE, Bruno TC, Moore BL, et al. Identification of shared TCR sequences from T cells in human breast cancer using emulsion RT-PCR. Proc Natl Acad Sci U S A. 2016;113(29):8272–7. https://doi.org/10.1073/pnas.1606994113.
103. Osman GE, Toda M, Kanagawa O, Hood LE. Characterization of the T cell receptor repertoire causing collagen arthritis in mice. J Exp Med. 1993;177(2):387–95.
104. Venturi V, Chin HY, Asher TE, Ladell K, Scheinberg P, Bornstein E, et al. TCR beta-chain sharing in human CD8+ T cell responses to cytomegalovirus and EBV. J Immunol. 2008;181(11):7853–62.
105. Sensi M, Farina C, Maccalli C, Lupetti R, Nicolini G, Anichini A, et al. Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine. J Clin Invest. 1997;99(4):710–7. https://doi.org/10.1172/jci119215.
106. Lim A, Trautmann L, Peyrat MA, Couedel C, Davodeau F, Romagne F, et al. Frequent contribution of T cell clonotypes with public TCR features to the chronic response against a dominant EBV-derived epitope: application to direct detection of their molecular imprint on the human peripheral T cell repertoire. J Immunol. 2000;165(4):2001–11.
107. Adams S, Leblanc P, Datta SK. Junctional region sequences of T-cell receptor beta-chain genes expressed by pathogenic anti-DNA autoantibody-inducing helper T cells from lupus mice: possible selection by cationic autoantigens. Proc Natl Acad Sci U S A. 1991;88(24):11271–5.
108. Johnston SL, Borson ND, Wettstein PJ. Spectratyping of TCRs expressed by CTL-infiltrating minor histocompatibility antigen-disparate allografts. J Immunol. 1997;159(11):5233–45.
109. Willhauck M, Scheibenbogen C, Pawlita M, Mohler T, Thiel E, Keilholz U. Restricted T-cell receptor repertoire in melanoma metastases regressing after cytokine therapy. Cancer Res. 2003;63(13):3483–5.
110. Nicolo C, Di Sante G, Orsini M, Rolla S, Columba-Cabezas S, Romano Spica V, et al. Mycobacterium tuberculosis in the adjuvant modulates the balance of Th immune response to self-antigen of the CNS without influencing a “core” repertoire of specific T cells. Int Immunol. 2006;18(2):363–74. https://doi.org/10.1093/intimm/dxh376.
111. Fujii Y, Hayasaka D, Kitaura K, Takasaki T, Suzuki R, Kurane I. T-cell clones expressing different T-cell receptors accumulate in the brains of dying and surviving mice after peripheral infection with far eastern strain of tick-borne encephalitis virus. Viral Immunol. 2011;24(4):291–302. https://doi.org/10.1089/vim.2011.0017.
112. Aas-Hanssen K, Funderud A, Thompson KM, Bogen B, Munthe LA. Idiotype-specific Th cells support oligoclonal expansion of anti-dsDNA B cells in mice with lupus. J Immunol. 2014;193(6):2691–8. https://doi.org/10.4049/jimmunol.1400640.
113. Hill BJ, Darrah PA, Ende Z, Ambrozak DR, Quinn KM, Darko S, et al. Epitope specificity delimits the functional capabilities of vaccine-induced CD8 T cell populations. J Immunol. 2014;193(11):5626–36. https://doi.org/10.4049/jimmunol.1401017.
114. Shirai K, Hayasaka D, Kitaura K, Takasaki T, Morita K, Suzuki R, et al. Qualitative differences in brain-infiltrating T cells are associated with a fatal outcome in mice infected with Japanese encephalitis virus. Arch Virol. 2015;160(3):765–75. https://doi.org/10.1007/s00705-014-2154-8.
115. Miyai M, Eikawa S, Hosoi A, Iino T, Matsushita H, Isobe M, et al. Detection and tracking of NY-ESO-1-specific CD8+ T cells by high-throughput T cell receptor beta (TCRB) gene rearrangements sequencing in a peptide-vaccinated patient. PLoS One. 2015;10(8):e0136086. https://doi.org/10.1371/journal.pone.0136086.
116. Campos-Lima PO, Levitsky V, Imreh MP, Gavioli R, Masucci MG. Epitope-dependent selection of highly restricted or diverse T cell receptor repertoires in response to persistent infection by Epstein-Barr virus. J Exp Med. 1997;186(1):83–9.
117. Slachta CA, Jeevanandam V, Goldman B, Lin WL, Platsoucas CD. Coronary arteries from human cardiac allografts with chronic rejection contain oligoclonal T cells: persistence of identical clonally expanded TCR transcripts from the early post-transplantation period (endomyocardial biopsies) to chronic rejection (coronary arteries). J Immunol. 2000;165(6):3469–83.
118. Boita M, Guida G, Circosta P, Elia AR, Stella S, Heffler E, et al. The molecular and functional characterization of clonally expanded CD8+ TCR BV T cells in eosinophilic granulomatosis with polyangiitis (EGPA). Clin Immunol. 2014;152(1–2):152–63. https://doi.org/10.1016/j.clim.2014.03.001.
119. Brandle D, Burki K, Wallace VA, Rohrer UH, Mak TW, Malissen B, et al. Involvement of both T cell receptor V alpha and V beta variable region domains and alpha chain junctional region in viral antigen recognition. Eur J Immunol. 1991;21(9):2195–202. https://doi.org/10.1002/eji.1830210930.
120. Clemente MJ, Przychodzen B, Jerez A, Dienes BE, Afable MG, Husseinzadeh H, et al. Deep sequencing of the T-cell receptor repertoire in CD8+ T-large granular lymphocyte leukemia identifies signature landscapes. Blood. 2013;122(25):4077–85. https://doi.org/10.1182/blood-2013-05-506386.
121. Iancu EM, Gannon PO, Laurent J, Gupta B, Romero P, Michielin O, et al. Persistence of EBV antigen-specific CD8 T cell clonotypes during homeostatic immune reconstitution in cancer patients. PLoS One. 2013;8(10):e78686. https://doi.org/10.1371/journal.pone.0078686.
122. Bowerman NA, Falta MT, Mack DG, Wehrmann F, Crawford F, Mroz MM, et al. Identification of multiple public TCR repertoires in chronic beryllium disease. J Immunol. 2014;192(10):4571–80. https://doi.org/10.4049/jimmunol.1400007.
123. Echchakir H, Asselin-Paturel C, Dorothee G, Vergnon I, Grunenwald D, Chouaib S, et al. Analysis of T-cell-receptor beta-chain-gene usage in peripheral-blood and tumor-infiltrating lymphocytes from human non-small-cell lung carcinomas. Int J Cancer. 1999;81(2):205–13.
124. Nguyen P, Liu W, Ma J, Manirarora JN, Liu X, Cheng C, et al. Discrete TCR repertoires and CDR3 features distinguish effector and Foxp3+ regulatory T lymphocytes in myelin oligodendrocyte glycoprotein-induced experimental allergic encephalomyelitis. J Immunol. 2010;185(7):3895–904. https://doi.org/10.4049/jimmunol.1001550.
125. Sensi M, Traversari C, Radrizzani M, Salvi S, Maccalli C, Mortarini R, et al. Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1. Proc Natl Acad Sci U S A. 1995;92(12):5674–8.
126. Goebels N, Hofstetter H, Schmidt S, Brunner C, Wekerle H, Hohlfeld R. Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence. Brain. 2000;123(Pt 3):508–18.
127. Berger CT, Frahm N, Price DA, Mothe B, Ghebremichael M, Hartman KL, et al. High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control. J Virol. 2011;85(18):9334–45. https://doi.org/10.1128/jvi.00460-11.
128. Hunsucker SA, McGary CS, Vincent BG, Enyenihi AA, Waugh JP, McKinnon KP, et al. Peptide/MHC tetramer-based sorting of CD8(+) T cells to a leukemia antigen yields clonotypes drawn nonspecifically from an underlying restricted repertoire. Cancer Immunol Res. 2015;3(3):228–35. https://doi.org/10.1158/2326-6066.cir-14-0001.
129. Wang F, Ono T, Kalergis AM, Zhang W, DiLorenzo TP, Lim K, et al. On defining the rules for interactions between the T cell receptor and its ligand: a critical role for a specific amino acid residue of the T cell receptor beta chain. Proc Natl Acad Sci U S A. 1998;95(9):5217–22.
130. Rizzuto GA, Merghoub T, Hirschhorn-Cymerman D, Liu C, Lesokhin AM, Sahawneh D, et al. Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med. 2009;206(4):849–66. https://doi.org/10.1084/jem.20081382.
131. Luo W, Ma L, Wen Q, Zhou M, Wang X. Analysis of the conservation of T cell receptor alpha and beta chain variable regions gene in pp65 peptide-specific HLA-A*0201-restricted CD8+ T cells. Cell Mol Immunol. 2009;6(2):105–10. https://doi.org/10.1038/cmi.2009.14.
132. Dahal-Koirala S, Risnes LF, Christophersen A, Sarna VK, Lundin KE, Sollid LM, et al. TCR sequencing of single cells reactive to DQ2.5-glia-alpha2 and DQ2.5-glia-omega2 reveals clonal expansion and epitope-specific V-gene usage. Mucosal Immunol. 2016;9(3):587–96. https://doi.org/10.1038/mi.2015.147.
133. Mackensen A, Ferradini L, Carcelain G, Triebel F, Faure F, Viel S, et al. Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma. Cancer Res. 1993;53(15):3569–73.
134. Fazou C, Yang H, McMichael AJ, Callan MF. Epitope specificity of clonally expanded populations of CD8+ T cells found within the joints of patients with inflammatory arthritis. Arthritis Rheum. 2001;44(9):2038–45. https://doi.org/10.1002/1529-0131(200109)44:9<2038::aid-art353>3.0.co;2-1.
135. Zhong W, Reinherz EL. In vivo selection of a TCR Vbeta repertoire directed against an immunodominant influenza virus CTL epitope. Int Immunol. 2004;16(11):1549–59. https://doi.org/10.1093/intimm/dxh156.
136. Clemens EB, Doherty PC, La Gruta NL, Turner SJ. Fixed expression of single influenza virus-specific TCR chains demonstrates the capacity for TCR alpha- and beta-chain diversity in the face of peptide-MHC class I specificity. J Immunol. 2015;194(3):898–910. https://doi.org/10.4049/jimmunol.1401792.
137. Iwashiro M, Kondo T, Shimizu T, Yamagishi H, Takahashi K, Matsubayashi Y, et al. Multiplicity of virus-encoded helper T-cell epitopes expressed on FBL-3 tumor cells. J Virol. 1993;67(8):4533–42.
138. Ferradini L, Mackensen A, Genevee C, Bosq J, Duvillard P, Avril MF, et al. Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion. J Clin Invest. 1993;91(3):1183–90. https://doi.org/10.1172/jci116278.
139. McKee MD, Clay TM, Diamond RA, Rosenberg SA, Nishimura MI. Quantitation of T-cell receptor frequencies by competitive polymerase chain reaction: dynamics of T-cell clonotype frequencies in an expanding tumor-infiltrating lymphocyte culture. J Immunother. 2000;23(4):419–29.
140. Menezes JS, van den Elzen P, Thornes J, Huffman D, Droin NM, Maverakis E, et al. A public T cell clonotype within a heterogeneous autoreactive repertoire is dominant in driving EAE. J Clin Invest. 2007;117(8):2176–85. https://doi.org/10.1172/jci28277.
141. Nakano N, Kikutani H, Nishimoto H, Kishimoto T. T cell receptor V gene usage of islet beta cell-reactive T cells is not restricted in non-obese diabetic mice. J Exp Med. 1991;173(5):1091–7.
142. Shilyansky J, Nishimura MI, Yannelli JR, Kawakami Y, Jacknin LS, Charmley P, et al. T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines. Proc Natl Acad Sci U S A. 1994;91(7):2829–33.
143. Deckhut AM, Allan W, McMickle A, Eichelberger M, Blackman MA, Doherty PC, et al. Prominent usage of V beta 8.3 T cells in the H-2Db-restricted response to an influenza A virus nucleoprotein epitope. J Immunol. 1993;151(5):2658–66.
144. Sensi M, Salvi S, Castelli C, Maccalli C, Mazzocchi A, Mortarini R, et al. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone. J Exp Med. 1993;178(4):1231–46.
145. Farina C, van der Bruggen P, Boel P, Parmiani G, Sensi M. Conserved TCR usage by HLA-Cw* 1601-restricted T cell clones recognizing melanoma antigens. Int Immunol. 1996;8(9):1463–6.
146. Skulina C, Schmidt S, Dornmair K, Babbe H, Roers A, Rajewsky K, et al. Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc Natl Acad Sci U S A. 2004;101(8):2428–33.
147. Robins HS, Srivastava SK, Campregher PV, Turtle CJ, Andriesen J, Riddell SR, et al. Overlap and effective size of the human CD8+ T cell receptor repertoire. Sci Transl Med. 2010;2(47):47ra64. https://doi.org/10.1126/scitranslmed.3001442.
148. Peggs K, Verfuerth S, Pizzey A, Ainsworth J, Moss P, Mackinnon S. Characterization of human cytomegalovirus peptide-specific CD8(+) T-cell repertoire diversity following in vitro restimulation by antigen-pulsed dendritic cells. Blood. 2002;99(1):213–23.
149. Zhou J, Dudley ME, Rosenberg SA, Robbins PF. Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma. J Immunol. 2004;173(12):7622–9.
150. Muraro PA, Robins H, Malhotra S, Howell M, Phippard D, Desmarais C, et al. T cell repertoire following autologous stem cell transplantation for multiple sclerosis. J Clin Invest. 2014;124(3):1168–72. https://doi.org/10.1172/jci71691.
151. Viret C, Mahiddine K, Baker RL, Haskins K, Guerder S. The T cell repertoire-diversifying enzyme TSSP contributes to thymic selection of diabetogenic CD4 T cell specificities reactive to ChgA and IAPP autoantigens. J Immunol. 2015;195(5):1964–73. https://doi.org/10.4049/jimmunol.1401683.
152. Eltahla AA, Rizzetto S, Pirozyan MR, Betz-Stablein BD, Venturi V, Kedzierska K, et al. Linking the T cell receptor to the single cell transcriptome in antigen-specific human T cells. Immunol Cell Biol. 2016;94(6):604–11. https://doi.org/10.1038/icb.2016.16.
153. Durinovic-Bello I, Steinle A, Ziegler AG, Schendel DJ. HLA-DQ-restricted, islet-specific T-cell clones of a type I diabetic patient. T-cell receptor sequence similarities to insulitis-inducing T-cells of nonobese diabetic mice. Diabetes. 1994;43(11):1318–25.
154. Echchakir H, Vergnon I, Dorothee G, Grunenwald D, Chouaib S, Mami-Chouaib F. Evidence for in situ expansion of diverse antitumor-specific cytotoxic T lymphocyte clones in a human large cell carcinoma of the lung. Int Immunol. 2000;12(4):537–46.
155. Hamel Y, Rohrlich P, Baron V, Bonhomme D, Rieux-Laucat F, Necker A, et al. Characterization of antigen-specific repertoire diversity following in vitro restimulation by a recombinant adenovirus expressing human cytomegalovirus pp65. Eur J Immunol. 2003;33(3):760–8. https://doi.org/10.1002/eji.200323628.
156. Kuball J, Schmitz FW, Voss RH, Ferreira EA, Engel R, Guillaume P, et al. Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity. 2005;22(1):117–29. https://doi.org/10.1016/j.immuni.2004.12.005.
157. Marino M, Maiuri MT, Di Sante G, Scuderi F, La Carpia F, Trakas N, et al. T cell repertoire in DQ5-positive MuSK-positive myasthenia gravis patients. J Autoimmun. 2014;52:113–21. https://doi.org/10.1016/j.jaut.2013.12.007.
158. Dufour E, Carcelain G, Gaudin C, Flament C, Avril MF, Faure F. Diversity of the cytotoxic melanoma-specific immune response: some CTL clones recognize autologous fresh tumor cells and not tumor cell lines. J Immunol. 1997;158(8):3787–95.
159. Tikochinski Y, Elias D, Steeg C, Marcus H, Kantorowitz M, Reshef T, et al. A shared TCR CDR3 sequence in NOD mouse autoimmune diabetes. Int Immunol. 1999;11(6):951–6.
160. Hogan LH, Wang M, Suresh M, Co DO, Weinstock JV, Sandor M. CD4+ TCR repertoire heterogeneity in Schistosoma mansoni-induced granulomas. J Immunol. 2002;169(11):6386–93.
161. Miles JJ, Silins SL, Brooks AG, Davis JE, Misko I, Burrows SR. T-cell grit: large clonal expansions of virus-specific CD8+ T cells can dominate in the peripheral circulation for at least 18 years. Blood. 2005;106(13):4412–3.
162. Aebischer T, Oehen S, Hengartner H. Preferential usage of V alpha 4 and V beta 10 T cell receptor genes by lymphocytic choriomeningitis virus glycoprotein-specific H-2Db-restricted cytotoxic T cells. Eur J Immunol. 1990;20(3):523–31. https://doi.org/10.1002/eji.1830200310.
163. Zarour H, De Smet C, Lehmann F, Marchand M, Lethe B, Romero P, et al. The majority of autologous cytolytic T-lymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide derived from gene Pmel17/gp100. J Invest Dermatol. 1996;107(1):63–7.
164. Stanislawski T, Voss RH, Lotz C, Sadovnikova E, Willemsen RA, Kuball J, et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol. 2001;2(10):962–70. https://doi.org/10.1038/ni1001-962.
165. Hiyane MI, Boscardin SB, Rodrigues MM. The non-palindromic adaptor-PCR method for the identification of the T-cell receptor genes of an interferon-gamma-secreting T-cell hybridomaspecific for trans-sialidase, an immunodominant Trypanosoma cruzi antigen. Braz J Med Biol Res. 2006;39(3):345–54.
166. •• Emerson RO, WS DW, Vignali M, Gravley J, Hu JK, Osborne EJ, et al. Immunosequencing identifies signatures of cytomegalovirus exposure history and HLA-mediated effects on the T cell repertoire. Nat Genet. 2017;49(5):659–65. https://doi.org/10.1038/ng.3822. This paper represents an essential step toward using immunosequencing data to differentiate type 1 diabetes patients from control subjects and ideally to predict disease progression. This paper identified TCRs associated with CMV serostatus, but the concept can likely be applied to type 1 diabetes research given sufficient samples and rescources.
167. Pathiraja V, Kuehlich JP, Campbell PD, Krishnamurthy B, Loudovaris T, Coates PT, et al. Proinsulin-specific, HLA-DQ8, and HLA-DQ8-transdimer-restricted CD4+ T cells infiltrate islets in type 1 diabetes. Diabetes. 2015;64(1):172–82. https://doi.org/10.2337/db14-0858.
168. •• Michels AW, Landry LG, McDaniel KA, Yu L, Campbell-Thompson M, Kwok WW, et al. Islet-derived CD4 T cells targeting proinsulin in human autoimmune diabetes. Diabetes. 2017;66(3):722–34. https://doi.org/10.2337/db16-1025. This paper describes autoreactive T cell clones, including epitope reactivities, isolated from the pancreas of human type 1 diabetes organ donors.
169. •• Babon JA, DeNicola ME, Blodgett DM, Crevecoeur I, Buttrick TS, Maehr R, et al. Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetes. Nat Med. 2016;22(12):1482–7. https://doi.org/10.1038/nm.4203. This paper describes autoreactive T cell clones, including epitope reactivities, isolated from the pancreas of human type 1 diabetes organ donors.
170. • Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964–74. https://doi.org/10.2337/dc15-1419. This is a consensus paper describing new clinical staging criteria for the diagnosis of type 1 diabetes with stage 1 disease being marked by multiple autoantibody positivity without dysglycemia and stage 2 representing the development of dysglycemia without overt symptomatic disease (i.e., type 1 diabetes diagnosis can be made prior to the requirement for insulin therapy).
171. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;383(9911):69–82. https://doi.org/10.1016/S0140-6736(13)60591-7.
172. Eisenbarth GS, Type I. Diabetes mellitus. A chronic autoimmune disease. N Engl J Med. 1986;314(21):1360–8. https://doi.org/10.1056/NEJM198605223142106.
173. •• Kracht MJ, van Lummel M, Nikolic T, Joosten AM, Laban S, van der Slik AR, et al. Autoimmunity against a defective ribosomal insulin gene product in type 1 diabetes. Nat Med. 2017;23(4):501–7. https://doi.org/10.1038/nm.4289. Seminal report of Defective Ribosomal Insulin Products (DRiPs) as novel autoantigens for type 1 diabetes.
174. •• Delong T, Wiles TA, Baker RL, Bradley B, Barbour G, Reisdorph R, et al. Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. Science. 2016;351(6274):711–4. https://doi.org/10.1126/science.aad2791. Seminal report of hybrid insulin peptides (HIPs) as novel autoantigens for type 1 diabetes.
175. •• Howie B, Sherwood AM, Berkebile AD, Berka J, Emerson RO, Williamson DW, et al. High-throughput pairing of T cell receptor alpha and beta sequences. Sci Transl Med. 2015;7(301):301ra131. https://doi.org/10.1126/scitranslmed.aac5624. This paper describes a key stride toward the ability to pair TCR alpha and beta chain sequences for TCR reconstruction.
176. Manual CSTU. http://www.clontech.com/xxclt_ibcGetAttachment.jsp?cItemId=114424. Accessed 30 June 2017.
177. Taylor S, Yasuyama N, Farmer A. A SMARTer approach to profiling the human T-cell receptor repertoire. 2016;196(1 Supplement):209.5.
178. Christley S, Levin M, Fonner J, Monson N, Rounds WH, Rubelt F et al. VDJPipe: a pre-processing pipeline for immune repertoire sequencing data. 2016;196(1 Supplement):209.26.
179. pRESTO. https://pypi.python.org/pypi/presto. Accessed 30 June 2017.
180. IgBLAST. ftp://ftp.ncbi.nih.gov/blast/executables/igblast/release/. Accessed 30 June 2017.
181. Ye J. An update on IgBLAST, a tool for Ig and TCR sequence analysis. 2016;196(1 Supplement):138.3.
182. MIGMAP. https://github.com/mikessh/migmap. Accessed 30 June 2017.
183. Decombinator. https://innate2adaptive.github.io/Decombinator/. Accessed 30 June 2017.
184. Thomas N, Heather J, Ndifon W, Shawe-Taylor J, Chain B. Decombinator: a tool for fast, efficient gene assignment in T-cell receptor sequences using a finite state machine. Bioinformatics. 2013;29(5):542–50. https://doi.org/10.1093/bioinformatics/btt004.
185. Stubbington MJ, Lonnberg T, Proserpio V, Clare S, Speak AO, Dougan G, et al. T cell fate and clonality inference from single-cell transcriptomes. Nat Methods. 2016;13(4):329–32. https://doi.org/10.1038/nmeth.3800.
186. TraCeR. https://github.com/teichlab/tracer. Accessed 30 June 2017.
187. Shugay M, Britanova OV, Merzlyak EM, Turchaninova MA, Mamedov IZ, Tuganbaev TR, et al. Towards error-free profiling of immune repertoires. Nat Methods. 2014;11(6):653–5. https://doi.org/10.1038/nmeth.2960.
188. MiGEC. https://github.com/mikessh/migec. Accessed 30 June 2017.
189. Kuchenbecker L, Nienen M, Hecht J, Neumann AU, Babel N, Reinert K, et al. IMSEQ--a fast and error aware approach to immunogenetic sequence analysis. Bioinformatics. 2015;31(18):2963–71. https://doi.org/10.1093/bioinformatics/btv309.
190. ImSeq. http://www.imtools.org/. Accessed 30 June 2017.
191. Gerritsen B, Pandit A, Andeweg AC, de Boer RJ. RTCR: a pipeline for complete and accurate recovery of T cell repertoires from high throughput sequencing data. Bioinformatics. 2016;32(20):3098–106. https://doi.org/10.1093/bioinformatics/btw339.
192. RTCR. https://github.com/uubram/RTCR. Accessed 30 June 2017.
193. Bolotin DA, Poslavsky S, Mitrophanov I, Shugay M, Mamedov IZ, Putintseva EV et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat Methods. 2015;12(5): 380–1. https://doi.org/10.1038/nmeth.3364.
194. MiXCR. https://mixcr.readthedocs.io/en/latest/quickstart.html. Accessed 30 June 2017.
195. Toby IT, Levin MK, Salinas EA, Christley S, Bhattacharya S, Breden F, et al. VDJML: a file format with tools for capturing the results of inferring immune receptor rearrangements. BMC Bioinformatics. 2016;17(Suppl 13):333. https://doi.org/10.1186/s12859-016-1214-3.
196. VDJserver. https://vdjserver.org. Accessed 30 June 2017.
197. Robins HS, Campregher PV, Srivastava SK, Wacher A, Turtle CJ, Kahsai O, et al. Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cells. Blood. 2009;114(19):4099–107. https://doi.org/10.1182/blood-2009-04-217604.
198. immunoSEQ. http://www.adaptivebiotech.com/immunoseq/. Accessed 30 June 2017.
199. iPair. http://www.irepertoire.com/ipair. Accessed 30 June 2017.
200. Bolen CR, Rubelt F, Vander Heiden JA, Davis MM. The repertoire dissimilarity index as a method to compare lymphocyte receptor repertoires. BMC Bioinformatics. 2017;18(1):155. https://doi.org/10.1186/s12859-017-1556-5.
201. RDI. https://bitbucket.org/cbolen1/rdicore/. Accessed 30 June 2017.
202. Dash P, Fiore-Gartland AJ, Hertz T, Wang GC, Sharma S, Souquette A, et al. Quantifiable predictive features define epitope-specific T cell receptor repertoires. Nature. 2017; https://doi.org/10.1038/nature22383.
203. TCRdist. https://github.com/phbradley/tcr-dist. Accessed 30 June 2017.
204. iRweb. http://www.irepertoire.com/irweb. Accessed 30 June 2017.
205. Loupe. https://support.10xgenomics.com/genome-exome/software/visualization/latest/what-is-loupe. Accessed 30 June 2017.
206. Nazarov VI, Pogorelyy MV, Komech EA, Zvyagin IV, Bolotin DA, Shugay M, et al. tcR: an R package for T cell receptor repertoire advanced data analysis. BMC Bioinformatics. 2015;16:175. https://doi.org/10.1186/s12859-015-0613-1.
207. tcR. https://imminfo.github.io/tcr. Accessed 30 June 2017.
208. Shugay M, Bagaev DV, Turchaninova MA, Bolotin DA, Britanova OV, Putintseva EV, et al. VDJtools: unifying post-analysis of T cell receptor repertoires. PLoS Comput Biol. 2015;11(11):e1004503. https://doi.org/10.1371/journal.pcbi.1004503.
209. VDJtools. https://vdjtools-doc.readthedocs.io/en/latest/intro.html. Accessed 30 June 2017.
210. Bagaev DV, Zvyagin IV, Putintseva EV, Izraelson M, Britanova OV, Chudakov DM, et al. VDJviz: a versatile browser for immunogenomics data. BMC Genomics. 2016;17:453. https://doi.org/10.1186/s12864-016-2799-7.
211. VDJviz. https://github.com/antigenomics/vdjviz. Accessed 30 June 2017.
212. Cao X, Wa Q, Wang Q, Li L, Liu X, An L, et al. High throughput sequencing reveals the diversity of TRB-CDR3 repertoire in patients with psoriasis vulgaris. Int Immunopharmacol. 2016;40:487–91. https://doi.org/10.1016/j.intimp.2016.10.004.
213. Guo C, Wang Q, Cao X, Yang Y, Liu X, An L, et al. High-throughput sequencing reveals immunological characteristics of the TRB-/IgH-CDR3 region of umbilical cord blood. J Pediatr. 2016;176:69–78.e1. https://doi.org/10.1016/j.jpeds.2016.05.078.
214. Fahnrich A, Krebbel M, Decker N, Leucker M, Lange FD, Kalies K, et al. ClonoCalc and ClonoPlot: immune repertoire analysis from raw files to publication figures with graphical user interface. BMC Bioinformatics. 2017;18(1):164. https://doi.org/10.1186/s12859-017-1575-2.
215. Kukurba K, Montgomery S. RNA sequencing and analysis. Cold Spring Harb Protoc. 2015;2015(11):951–69.
216. Newell EW, Davis MM. Beyond model antigens: high-dimensional methods for the analysis of antigen-specific T cells. Nat Biotechnol. 2014;32(2):149–57. https://doi.org/10.1038/nbt.2783.
217. •• Zheng GXY, Terry JM, Belgrader P, Ryvkin P, Bent ZW, Wilson R, et al. Massively parallel digital transcriptional profiling of single cells. Nat Commun. 2017;8:14049. https://doi.org/10.1038/ncomms14049. This paper reports single-cell immunosequencing which will be an imperative step toward identifying cell function/phenotype along with TCR clone/reactivity.
218. Ziegler AG, Rewers M, Simell O, Simell T, Lempainen J, Steck A, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013;309(23):2473–9. https://doi.org/10.1001/jama.2013.6285.
219. Lebastchi J, Herold KC. Immunologic and metabolic biomarkers of beta-cell destruction in the diagnosis of type 1 diabetes. Cold Spring Harb Perspect Med. 2012;2(6):a007708. https://doi.org/10.1101/cshperspect.a007708.
220. • Wu J, Jia S, Wang C, Zhang W, Liu S, Zeng X, et al. Minimal residual disease detection and evolved IGH clones analysis in acute B lymphoblastic leukemia using IGH deep sequencing. Front Immunol. 2016;7:403. https://doi.org/10.3389/fimmu.2016.00403. This paper supports the notion that immunosequencing offers sufficient specificity and sensitivity to potentially detect minimal resisual autoimmune disease (similar to monitoring MRD in leukemia patients). This suggests that immunosequencing could be used to monitor patients’ response to therapy and determine if a redose may be necessary.
221. Weng WK, Armstrong R, Arai S, Desmarais C, Hoppe R, Kim YH. Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma. Sci Transl Med. 2013;5(214):214ra171. https://doi.org/10.1126/scitranslmed.3007420.
222. Logan AC, Vashi N, Faham M, Carlton V, Kong K, Buno I, et al. Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival. Biol Blood Marrow Transplant. 2014;20(9):1307–13. https://doi.org/10.1016/j.bbmt.2014.04.018.
223. Faham M, Zheng J, Moorhead M, Carlton VE, Stow P, Coustan-Smith E, et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood. 2012;120(26):5173–80. https://doi.org/10.1182/blood-2012-07-444042.
224. von Herrath M, Sanda S, Herold K. Type 1 diabetes as a relapsing-remitting disease? Nat Rev Immunol. 2007;7(12):988–94. https://doi.org/10.1038/nri2192.
225. Thelin MA, Kissler S, Vigneault F, Watters AL, White D, Koshy ST, et al. In vivo enrichment of diabetogenic T cells. Diabetes. 2017; https://doi.org/10.2337/db16-0946.
226. Belzer FO, Schweizer RT, Cho S, Cochrum KC, Moberg A, Kountz SL. Efficacy of antilymphocyte globulin in cadaver renal transplantation. Surg Forum. 1971;22:223–4.
227. Birtch AG, Carpenter CB, Tilney NL, Hampers CL, Hager FB, Levine L, et al. Controlled clinical trial of antilymphocyte globulin in human renal allografts. Transplant Proc. 1971;3(1):762–5.
228. Griepp RB, Stinson EB, Dong E Jr, Phillips RC, Morrell RM, Shumway NE. Use of antithymocyte globulin in human heart transplantation. Circulation. 1972;45(5 Suppl 1):I147–53.
229. Storb R, Blume KG, O'Donnell MR, Chauncey T, Forman SJ, Deeg HJ, et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. Biol Blood Marrow Transplant. 2001;7(1):39–44. https://doi.org/10.1053/bbmt.2001.v7.pm11215697.
230. Yussim A, Shapira Z. Single-bolus high-dose ATG for prophylaxis of rejection in renal transplantation—a prospective, randomized study. Transpl Int. 2000;13(Suppl 1):S293–4.
231. Bhise V, Dhib-Jalbut S. Further understanding of the immunopathology of multiple sclerosis: impact on future treatments. Expert Rev Clin Immunol. 2016;12(10):1069–89. https://doi.org/10.1080/1744666x.2016.1191351.
232. Semerano L, Minichiello E, Bessis N, Boissier MC. Novel immunotherapeutic avenues for rheumatoid arthritis. Trends Mol Med. 2016;22(3):214–29. https://doi.org/10.1016/j.molmed.2016.01.005.
233. Daifotis AG, Koenig S, Chatenoud L, Herold KC. Anti-CD3 clinical trials in type 1 diabetes mellitus. Clin Immunol. 2013;149(3):268–78. https://doi.org/10.1016/j.clim.2013.05.001.
234. Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function. Diabetes. 2012; https://doi.org/10.2337/db12-0049.
235. Gottlieb PA, Quinlan S, Krause-Steinrauf H, Greenbaum CJ, Wilson DM, Rodriguez H, et al. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes. Diabetes Care. 2010;33(4):826–32. https://doi.org/10.2337/dc09-1349.
236. Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;378(9789):412–9. https://doi.org/10.1016/S0140-6736(11)60886-6.
237. Ehlers MR, Nepom GT. Immune-directed therapy for type 1 diabetes at the clinical level: the Immune Tolerance Network (ITN) experience. Rev Diabet Stud. 2012;9(4):359–71. https://doi.org/10.1900/rds.2012.9.359.
238. Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet. 2013;381(9881):1905–15. https://doi.org/10.1016/S0140-6736(13)60023-9.
239. Feutren G, Assan R, Karsenty G, Du Rostu H, Sirmai J, Papos L, et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset: results of a multicentre double-blind trial. Lancet. 1986;328(8499):119–24. https://doi.org/10.1016/S0140-6736(86)91943-4.
240. Assan R, Feutren G, Debray-Sachs M, Quiniou-Debrie MC, Laborie C, Thomas G, et al. Metabolic and immunological effects of cyclosporin in recently diagnosed type 1 diabetes mellitus. Lancet. 1985;1(8420):67–71.
241. Sobel DO, Henzke A, Abbassi V. Cyclosporin and methotrexate therapy induces remission in type 1 diabetes mellitus. Acta Diabetol. 2010;47(3):243–50. https://doi.org/10.1007/s00592-010-0188-2.
242. Hagopian W, Ferry RJ Jr, Sherry N, Carlin D, Bonvini E, Johnson S, et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protege trial. Diabetes. 2013;62(11):3901–8. https://doi.org/10.2337/db13-0236.
243. Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013;62(11):3766–74. https://doi.org/10.2337/db13-0345.
244. Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, et al. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia. 2013;56(2):391–400. https://doi.org/10.1007/s00125-012-2753-4.
245. Orban T, Bundy B, Becker DJ, Dimeglio LA, Gitelman SE, Goland R, et al. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care. 2014;37(4):1069–75. https://doi.org/10.2337/dc13-0604.
246. Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Rosenthal SM, Shuster JJ, et al. Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes. J Clin Invest. 2015;125(1):448–55. https://doi.org/10.1172/JCI78492.
247. Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Perry DJ, Schultz AR, et al. Antithymocyte globulin plus G-CSF combination therapy leads to sustained immunomodulatory and metabolic effects in a subset of responders with established type 1 diabetes. Diabetes. 2016;65(12):3765–75. https://doi.org/10.2337/db16-0823.
248. Cabrera SM, Wang X, Chen YG, Jia S, Kaldunski ML, Greenbaum CJ, et al. Interleukin-1 antagonism moderates the inflammatory state associated with type 1 diabetes during clinical trials conducted at disease onset. Eur J Immunol. 2016;46(4):1030–46. https://doi.org/10.1002/eji.201546005.
249. Gitelman SE, Gottlieb PA, Felner EI, Willi SM, Fisher LK, Moran A, et al. Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial. Diabetologia. 2016; https://doi.org/10.1007/s00125-016-3917-4.
250. Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest. 2015;125(8):3285–96. https://doi.org/10.1172/jci81722.
251. Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2007;297(14):1568–76. https://doi.org/10.1001/jama.297.14.1568.
252. D’Addio F, Valderrama Vasquez A, Ben Nasr M, Franek E, Zhu D, Li L, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in new-onset type 1 diabetes: a multicenter analysis. Diabetes. 2014;63(9):3041–6. https://doi.org/10.2337/db14-0295.
253. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia. 2007;21(7):1387–94. https://doi.org/10.1038/sj.leu.2404683.
254. Bendall LJ, Bradstock KF. G-CSF: from granulopoietic stimulant to bone marrow stem cell mobilizing agent. Cytokine Growth Factor Rev. 2014;25(4):355–67. https://doi.org/10.1016/j.cytogfr.2014.07.011.
255. Jaspers JE, Brentjens RJ. Development of CAR T cells designed to improve antitumor efficacy and safety. Pharmacol Ther. 2017; https://doi.org/10.1016/j.pharmthera.2017.03.012.
256. Scarfo I, Maus MV. Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment. J Immunother Cancer. 2017;5:28. https://doi.org/10.1186/s40425-017-0230-9.
257. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517–28. https://doi.org/10.1016/s0140-6736(14)61403-3.
258. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116(20):4099–102. https://doi.org/10.1182/blood-2010-04-281931.
259. Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 2010;70(22):9053–61. https://doi.org/10.1158/0008-5472.can-10-2880.
260. Birkholz K, Hombach A, Krug C, Reuter S, Kershaw M, Kampgen E, et al. Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer. Gene Ther. 2009;16(5):596–604. https://doi.org/10.1038/gt.2008.189.
261. Brusko TM, Koya RC, Zhu S, Lee MR, Putnam AL, McClymont SA, et al. Human antigen-specific regulatory T cells generated by T cell receptor gene transfer. PLoS One. 2010;5(7):e11726. https://doi.org/10.1371/journal.pone.0011726.
262. Gravano DM, Vignali DA. The battle against immunopathology: infectious tolerance mediated by regulatory T cells. Cell Mol Life Sci. 2012;69(12):1997–2008. https://doi.org/10.1007/s00018-011-0907-z.
263. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol. 2002;2(2):85–95. https://doi.org/10.1038/nri724.
264. Smith CE, Miller SD. Multi-peptide coupled-cell tolerance ameliorates ongoing relapsing EAE associated with multiple pathogenic autoreactivities. J Autoimmun. 2006;27(4):218–31. https://doi.org/10.1016/j.jaut.2006.12.002.
265. Getts DR, Martin AJ, McCarthy DP, Terry RL, Hunter ZN, Yap WT, et al. Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nat Biotechnol. 2012;30(12):1217–24. https://doi.org/10.1038/nbt.2434.
266. Jones BS, Lamb LS, Goldman F, Di Stasi A. Improving the safety of cell therapy products by suicide gene transfer. Front Pharmacol. 2014;5:254. https://doi.org/10.3389/fphar.2014.00254.